N9284
Nitroreductase from Escherichia coli
≥90% (SDS-PAGE), recombinant, expressed in E. coli
Synonyme(s) :
NTRA
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Produits recommandés
![Nitrate Reductase (NAD[P]H) from Aspergillus niger lyophilized powder, ≥300 units/g solid](/deepweb/assets/sigmaaldrich/product/images/309/282/2a67ae4d-ca55-4f0b-96ec-34748ff8a21e/640/2a67ae4d-ca55-4f0b-96ec-34748ff8a21e.jpg)
Produit recombinant
expressed in E. coli
Niveau de qualité
Pureté
≥90% (SDS-PAGE)
Forme
lyophilized powder
Activité spécifique
≥100 units/mL
Poids mol.
monomer 24000
Caractéristiques du produit alternatif plus écologique
Waste Prevention
Safer Solvents and Auxiliaries
Design for Energy Efficiency
Learn more about the Principles of Green Chemistry.
sustainability
Greener Alternative Product
Numéro d'accès UniProt
Autre catégorie plus écologique
Conditions d'expédition
wet ice
Température de stockage
−20°C
Informations sur le gène
Escherichia coli K12 ... nfsB(945483)
Description générale
Nitroreductase is a flavoprotein and is encoded by the NfsB gene. It comprises a dimer, with 217 amino acids and active site in each subunit. The structure has FMN and the substrate bound to the enzyme.
Application
Nitroreductase from Escherichia coli has been used in the conjugation generation with pig liver esterase (PLE). It has also been used in chemiluminescence response studies with probes HyCL-3 and HyCL-4-AM in rat liver microsomes.
Actions biochimiques/physiologiques
Nitroreductase (NTR) catalyzes the reduction of nitroaromatic substrates and quinones. The mutant F124K of NTR is useful in cancer therapy and improves sensitization of drug CB1954.
Nitroreductase increases the sensitivity of organisms to nitro-containing drugs such as metronidazole by converting the nitro group to a cytotoxic nitro radical.
Nitroreductases can play a crucial role in redox systems via NADPH or NADH as a reductant.
Shows ability to reduce quinines. Enzyme for activating prodrugs in antibody directed enzyme prodrug therapy.
Propriétés physiques
Lyophilized powder containing PBS. Does not contain BSA as excipient
Définition de l'unité
One unit will reduce one μmole of Cytochrome C per minute in the presence of Menadione and NADH at pH 7.4 at 37 °C.
Notes préparatoires
Produced using animal component-free materials.
Code de la classe de stockage
13 - Non Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Les clients ont également consulté
Sébastien Jenni et al.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 248, 119179-119179 (2020-11-30)
The ever-growing demand for fluorogenic dyes usable in the rapid construction of analyte-responsive fluorescent probes, has recently contributed to a revival of interest in the chemistry of diketopyrrolopyrrole (DPP) pigments. In this context, we have explored the potential of symmetrical
G M Anlezark et al.
Biochemical pharmacology, 50(5), 609-618 (1995-08-25)
A nitroreductase isolated and purified from Escherichia coli B has been demonstrated to have potential applications in ADEPT (antibody-directed enzyme prodrug therapy) by its ability in vitro to reduce dinitrobenzamides (e.g. 5-aziridinyl 2,4-dinitrobenzamide, CB 1954 and its bischloroethylamino analogue, SN
M J Lemmon et al.
Gene therapy, 4(8), 791-796 (1997-08-01)
A fundamental obstacle in gene therapy for cancer treatment is the specific delivery of an anticancer gene product to a solid tumor. Although several strategies exist to control gene expression once a vector is directly introduced into a tumor, as
Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954
Grove JI, et al.
Cancer research, 63(17), 5532-5537 (2003)
Mckayla Stevens et al.
Bioorganic & medicinal chemistry, 28(22), 115710-115710 (2020-10-03)
In two previous studies, we identified compound 1 as a moderate GroEL/ES inhibitor with weak to moderate antibacterial activity against Gram-positive and Gram-negative bacteria including Bacillus subtilis, methicillin-resistant Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumannii, and SM101 Escherichia coli (which has
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique